Absci Corp (ABSI) - Total Liabilities
Based on the latest financial reports, Absci Corp (ABSI) has total liabilities worth $23.62 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Absci Corp - Total Liabilities Trend (2019–2025)
This chart illustrates how Absci Corp's total liabilities have evolved over time, based on quarterly financial data. See ABSI current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Absci Corp Competitors by Total Liabilities
The table below lists competitors of Absci Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Cultural Investment Holdings Co Ltd
SHG:600715
|
China | CN¥492.87 Million |
|
JinkoSolar Holding Company Limited
NYSE:JKS
|
USA | $90.73 Billion |
|
CTS International Logistics Corp Ltd
SHG:603128
|
China | CN¥6.06 Billion |
|
Neway CNC Equipment Suzhou Co Ltd
SHG:688697
|
China | CN¥2.57 Billion |
|
Gui Zhou Tyre Co Ltd
SHE:000589
|
China | CN¥9.79 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$46.36 Million |
|
Chengdu Information Technology of Chinese Academy of Sciences Co Ltd
SHE:300678
|
China | CN¥381.12 Million |
|
Changjiang & Jinggong Steel Building Group Co Ltd
SHG:600496
|
China | CN¥17.25 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down Absci Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ABSI market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.59 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Absci Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Absci Corp (2019–2025)
The table below shows the annual total liabilities of Absci Corp from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $26.85 Million | -22.12% |
| 2024-12-31 | $34.48 Million | -16.16% |
| 2023-12-31 | $41.12 Million | -11.74% |
| 2022-12-31 | $46.59 Million | -22.46% |
| 2021-12-31 | $60.09 Million | +178.65% |
| 2020-12-31 | $21.56 Million | -64.43% |
| 2019-12-31 | $60.63 Million | -- |
About Absci Corp
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the… Read more